Transformation from Small Cell to Squamous Cell Carcinoma in a Thymic Carcinoma Patient with a Durable Response to Anlotinib: A Case Report

被引：3

作者：

Qin, Wenru ^{[1
,2
]}

Zou, Bing ^{[2
]}

Fan, Xinyu ^{[2
,3
]}

Fan, Bingjie ^{[2
]}

Wang, Shijiang ^{[2
]}

Wang, Linlin ^{[2
]}

机构：

[1] Weifang Med Univ, Dept Oncol, Weifang, Shandong, Peoples R China

[2] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jiyan Rd 440, Jinan 250117, Shandong, Peoples R China

[3] Shandong Univ, Cheeloo Coll Med, Dept Oncol, Jinan, Shandong, Peoples R China

来源：

CANCER MANAGEMENT AND RESEARCH | 2022年 / 14卷

关键词：

thymic carcinoma; squamous cell carcinoma; small cell carcinoma; histologic transformation; anlotinib; ADENOCARCINOMA; CANCER;

D O I：

10.2147/CMAR.S362858

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The most common pathologic type of thymic carcinoma (TC) is squamous cell carcinoma (SCC). Small cell carcinoma is relatively rare, accounting for approximately 2% to 5% of all thymic tumors. Histologic transformation of TC has not yet been reported. Available treatments for TC patients who progress after first-line therapy are limited, which contributes to their poor prognosis. We reported an extraordinary case of a 66-year-old man who was diagnosed with thymic small cell carcinoma that transformed into SCC after third-line treatment. Surprisingly, the patient had a progression-free survival (PFS) of 25 months and an overall survival (OS) of 10 years on anlotinib as fourth-line therapy. The tolerance was well. Thus, anlotinib may be a safe and promising treatment for TC patients, especially those who undergo histologic transformation. cell small cell anlotinib

引用

页码：1595 / 1602

页数：8

共 22 条

[1] Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study [J].

Cheng, Ying ;

Wang, Qiming ;

Li, Kai ;

Shi, Jianhua ;

Liu, Ying ;

Wu, Lin ;

Han, Baohui ;

Chen, Gongyan ;

He, Jianxing ;

Wang, Jie ;

Lou, Donghua ;

Yu, Hao ;

Wang, Shanchun ;

Qin, Haifeng ;

Li, Xiaoling .

BRITISH JOURNAL OF CANCER, 2021, 125 (03) :366-371

[2] Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial [J].

Cheng, Ying ;

Han, Baohui ;

Li, Kai ;

Wang, Qiming ;

Zhang, Li ;

Shi, Jianhua ;

Wang, Zhehai ;

He, Jianxing ;

Shi, Yuankai ;

Chen, Weiqiang ;

Wang, Xiuwen ;

Luo, Yi ;

Nan, Kejun ;

Jin, Faguang ;

Li, Baolan ;

Zhu, Jing .

CANCER MEDICINE, 2020, 9 (08) :2621-2630

[3] Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus [J].

Cimpean, Anca Maria ;

Raica, Marius ;

Encica, Svetlana ;

Cornea, Remus ;

Bocan, Viorica .

ANNALS OF ANATOMY-ANATOMISCHER ANZEIGER, 2008, 190 (03) :238-245

[4] Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors [J].

Dorantes-Heredia, Rita ;

Manuel Ruiz-Morales, Jose ;

Cano-Garcia, Fernando .

TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (04) :401-412

[5] Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis [J].

Fukuda, Akito ;

Okuma, Yusuke ;

Hakozaki, Taiki ;

Mirokuji, Kie ;

Yomota, Makiko ;

Hishima, Tsunekazu ;

Hosomi, Yukio .

FRONTIERS IN ONCOLOGY, 2022, 11

[6] Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing [J].

Gerlinger, Marco ;

Rowan, Andrew J. ;

Horswell, Stuart ;

Larkin, James ;

Endesfelder, David ;

Gronroos, Eva ;

Martinez, Pierre ;

Matthews, Nicholas ;

Stewart, Aengus ;

Tarpey, Patrick ;

Varela, Ignacio ;

Phillimore, Benjamin ;

Begum, Sharmin ;

McDonald, Neil Q. ;

Butler, Adam ;

Jones, David ;

Raine, Keiran ;

Latimer, Calli ;

Santos, Claudio R. ;

Nohadani, Mahrokh ;

Eklund, Aron C. ;

Spencer-Dene, Bradley ;

Clark, Graham ;

Pickering, Lisa ;

Stamp, Gordon ;

Gore, Martin ;

Szallasi, Zoltan ;

Downward, Julian ;

Futreal, P. Andrew ;

Swanton, Charles .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (10) :883-892

[7] Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors [J].

Gong, Jay ;

Gregg, Jeffrey P. ;

Ma, Weijie ;

Yoneda, Ken ;

Moore, Elizabeth H. ;

Daly, Megan E. ;

Zhang, Yanhong ;

Williams, Melissa J. ;

Li, Tianhong .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (04) :297-301

[8] Change of Pathological Type to Metaplastic Squamous Cell Carcinoma of the Breast During Disease Recurrence: Case Report and Literature Review [J].

Guo, Tianhui ;

Chen, Zhiying ;

Xu, Jinpeng ;

Zhang, Yongchun .

FRONTIERS IN ONCOLOGY, 2020, 10

[9] Combined Small and Squamous Transformation in EGFR-mutated Lung Adenocarcinoma [J].

Hakozaki, Taiki ;

Kitazono, Miyako ;

Takamori, Mikio ;

Kiriu, Takahiro .

INTERNAL MEDICINE, 2020, 59 (10) :1291-1294

[10] Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302) [J].

Han, Baohui ;

Li, Kai ;

Zhao, Yizhuo ;

Li, Baolan ;

Cheng, Ying ;

Zhou, Jianying ;

Lu, You ;

Shi, Yuankai ;

Wang, Zhehai ;

Jiang, Liyan ;

Luo, Yi ;

Zhang, Yiping ;

Huang, Cheng ;

Li, Qiang ;

Wu, Guoming .

BRITISH JOURNAL OF CANCER, 2018, 118 (05) :654-661

← 1 2 3 →